Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach

Figure 3 Shows the mechanisms of cardiorenal therapeutic benefits of glucagon-like insulinotropic peptide-1 receptor agonists, sodium-glucose co-transporter 2 inhibitors, and their combination. LDL: Low density lipoprotein cholesterol; CV: Cardiovascular; MACE: Major adverse cardiac event; HF: Heart failure; CKD: Chronic kidney disease; GLP1RA: Glucagon-like insulinotropic peptide-1 receptor agonists; SGLT2i: Sodium-glucose co-transporter 2 inhibitor.